XML 20 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Net Loss Per Share (Tables)
 9 Months Ended
Sep. 30, 2014
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following tables reconcile the components of the numerator and denominator included in the calculations of diluted loss per share:

Three Months Ended September 30,

2014

2013
Numerator



Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(7,177,575
)

$
(30,877,410
)
Reflect adjustment for decrease in fair value of warrant liability
(271,022
)

—

Numerator for use in diluted loss per share
$
(7,448,597
)

$
(30,877,410
)




Denominator



Weighted average number of common shares outstanding
60,392,911


47,989,039

Effect of dilutive potential common shares from warrants
209,920


—

Denominator for use in diluted loss per share
60,602,831


47,989,039

 
 
 
 
Net loss per share, diluted
$
(0.12
)
 
$
(0.64
)

 
Nine Months Ended September 30,
 
2014
 
2013
Numerator
 
 
 
Net loss attributable to Inovio Pharmaceuticals, Inc.
$
(28,710,309
)
 
$
(50,574,118
)
Reflect adjustment for decrease in fair vale of warrant liability
(1,996,544
)
 
—

Numerator for use in diluted loss per share
$
(30,706,853
)
 
$
(50,574,118
)
 
 
 
 
Denominator
 
 
 
Weighted average number of common shares outstanding
58,625,740

 
44,045,769

Effect of dilutive potential common shares from warrants
310,674

 
—

Denominator for use in diluted loss per share
58,936,414

 
44,045,769

 
 
 
 
Net loss per share, diluted
$
(0.52
)
 
$
(1.15
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table summarizes potential common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect:
 
As of September 30,
Common Stock Equivalents
2014
 
2013
Options to purchase common stock
4,833,877

 
4,245,550

Warrants to purchase common stock
978,052

 
3,659,815

Convertible preferred stock
8,456

 
9,558

Total
5,820,385

 
7,914,923